ASTELLAS PHARMA
At Astellas, our vision is to be at the forefront of healthcare change by turning innovative science into meaningful VALUE for patients. As a specialty global pharmaceutical company, we focus on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. Together with our partners, we aim to lead in the areas where we can deliver the greatest value, with a focus on immuno-oncology, gene the... rapy, mitochondria, blindness and regeneration and targeted protein degradation. Astellas operates its business in approximately 70 countries around the world. It has approximately 14,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2022 financial results, revenue achieved about 1,500 billion yen (ca.$11 billion*), and R&D expenses were about 280 billion yen (ca.$2.0 billion*). *The exchange rate for the yen, 1USD: 142yen
ASTELLAS PHARMA
Industry:
Biotechnology Health Care Medical
Founded:
2005-04-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.astellas.com
Total Employee:
10001+
Status:
Active
Contact:
+81-3-3244-3000
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Maps LetsEncrypt Mobile Non Scaleable Content IPv6 Google Analytics 4 Google Google Cloud
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-12-21 | Propella | Propella acquired by Astellas Pharma | N/A |
| 2023-04-30 | IVERIC bio | IVERIC bio acquired by Astellas Pharma | 5.9 B USD |
| 2020-10-15 | Iota Biosciences | Iota Biosciences acquired by Astellas Pharma | 127.5 M USD |
| 2020-04-21 | Nanna Therapeutics | Nanna Therapeutics acquired by Astellas Pharma | 12 M GBP |
| 2019-12-26 | Xyphos Biosciences | Xyphos Biosciences acquired by Astellas Pharma | N/A |
| 2019-12-02 | Audentes Therapeutics | Audentes Therapeutics acquired by Astellas Pharma | 3 B USD |
| 2018-12-14 | Potenza Therapeutics | Potenza Therapeutics acquired by Astellas Pharma | 405 M USD |
| 2018-08-10 | Quethera | Quethera acquired by Astellas Pharma | 109 M USD |
| 2018-02-13 | Universal Cells Inc. | Universal Cells Inc. acquired by Astellas Pharma | N/A |
| 2017-12-01 | Mitobridge | Mitobridge acquired by Astellas Pharma | N/A |
Investors List
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Astellas Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-08-07 | Poseida Therapeutics | Astellas Pharma investment in Post-IPO Equity - Poseida Therapeutics | 50 M USD |
| 2022-10-24 | Taysha Gene Therapies | Astellas Pharma investment in Post-IPO Equity - Taysha Gene Therapies | 50 M USD |
| 2021-11-04 | The National Comprehensive Cancer Network (NCCN) | Astellas Pharma investment in Grant - The National Comprehensive Cancer Network (NCCN) | N/A |
| 2019-10-06 | LabCentral | Astellas Pharma investment in Corporate Round - LabCentral | 13 M USD |
| 2018-12-27 | Iota Biosciences | Astellas Pharma investment in Series A - Iota Biosciences | 15 M USD |
| 2017-11-15 | Catalia Health | Astellas Pharma investment in Grant - Catalia Health | 12.5 K USD |
| 2013-10-04 | Mitobridge | Astellas Pharma investment in Series A - Mitobridge | 5.22 M USD |
| 2012-04-24 | Telsar Pharma | Astellas Pharma investment in Series A - Telsar Pharma | 14 M USD |
| 2008-06-05 | CoMentis | Astellas Pharma investment in Series D - CoMentis | 20 M USD |
| 2005-02-17 | FibroGen | Astellas Pharma investment in Venture Round - FibroGen | 100 M USD |
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-05 | Chutes & Ladders—Astellas shakes up leadership with two new C-suite execs |
Official Site Inspections
http://www.astellas.com Semrush global rank: 218.11 K Semrush visits lastest month: 196.55 K
- Host name: 23.96.32.128
- IP address: 23.96.32.128
- Location: Washington United States
- Latitude: 38.7095
- Longitude: -78.1539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 22747
More informations about "Astellas Pharma"
Home | Astellas Pharma Canada, Inc.
Oct 26, 2016 Astellas stands on the forefront of healthcare change, turning innovative science into value for patients. Corporate Social Sustainability Astellas upholds our corporate responsibility to contribute to the sustainable …See details»
Global Management Structure | Astellas Pharma Inc.
At a Glance | Astellas Pharma Inc.
Business operations on a global scale. Astellas was formed in 2005 after the merger of Yamanouchi Pharmaceutical Co., Ltd. and the Fujisawa Pharmaceutical Co., Ltd. "Astellas" expresses the idea of "aspired stars" and …See details»
Corporate Governance | Astellas Pharma Inc.
Astellas' Corporate Governance. We aim to sustainably enhance corporate value by being chosen and trusted by all stakeholders. Search. Search. Top Menu About. Corporate Strategic Plan 2021. Corporate Strategic Plan 2021 …See details»
Astellas Pharma - Wikipedia
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of …See details»
Astellas Pharma - The Org
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and …See details»
Astellas Pharma - Crunchbase Company Profile
Astellas Pharma is a global pharmaceutical research & development company. Business Wire — Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: 60 Drugs Currently in Trials with 1 Approved …See details»
Org Chart Astellas Pharma - The Official Board
The org chart of Astellas Pharma contains its 89 main executives including Naoki Okamura, Atsushi Kitamura and Adam Pearson.See details»
Astellas Pharma US, Inc. | News Room - Articles
In her new position, Fenicchia will guide efforts to operationalize Astellas’ world-class commercial capabilities to achieve the overall objectives of the new organization. She has more than 25 years of experience in the pharmaceutical …See details»
About | Astellas Pharma Inc.
Astellas aims to stand on the forefront of healthcare change, turning innovative science into VALUE for patients and will continually strive to fulfill the expectations of our stakeholders and society. Read more Philosophy. Read …See details»
Astellas Gene Therapies - Crunchbase Company Profile & Funding
Astellas Gene Therapies is located in San Francisco, California, United States. Who are Astellas Gene Therapies 's competitors? Alternatives and possible competitors to Astellas Gene …See details»
Astellas Pharma - LinkedIn
Astellas has been working with the organization City Cancer Challenge (C/Can) to improve cancer outcomes in Arequipa, Peru, since 2022. The healthcare system in Peru is highly underfunded …See details»
Home | Astellas Clinical Trials
Our VISION at Astellas is to turn innovative science into VALUE for patients. The purpose of this website is to offer education and information to patients and their families and friends, the …See details»
Areas of Research | Astellas Clinical Trials
At Astellas, our vision is to contribute to improving the health of people around the world by developing, safe, innovative and effective treatments that bring hope to patients worldwide. …See details»
ABOUT US - Astellas Gene Therapies
Smethurst joined Astellas Gene Therapies in August 2021, transitioning from a leadership role in Astellas’ global regulatory organization. A global leader with over 25 years of experience in …See details»
Our People | Astellas Pharma Inc.
Astellas aims to be an “Employer of Choice: A company that is chosen by its current and future employees,” and we are investing time and energy into various initiatives to reach that goal. …See details»
Astellas Pharma US, Inc. | News Room - Articles
“Patient Focus” is the first of five core values that define our Astellas Way culture. To ensure we are sincerely living this pillar, we established the Patient Experience Organization last …See details»
Astellas Announces Leadership Changes in Canada and U.S.
Jan 8, 2018 Steve Sabus appointed to General Manager of Astellas Pharma Canada; Lynn Fenicchia Gerber and Kevin O'Keefe promoted to new roles in U.S. Sales Organization. …See details»
Astellas Pharma Canada, Inc. named as one of Canada's Best
Apr 14, 2021 Astellas ranked 38 on the Best Workplaces™ in Canada list . MARKHAM, ON, April 14, 2021 /CNW/ - Astellas Pharma Canada, Inc. has been recognized on the 2021 list of …See details»